RA
RPRX

Royce & Associates’s Repros Therapeutics Inc. RPRX Stock Holding History

Royce & Associates’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-129,000
Closed -$156K – 1178
2015
Q4 		$156K Hold
129,000
– – ﹤0.01% 1081
2015
Q3 		$958K Sell
129,000
-62,000
-32% -$474K 0.01% 968
2015
Q2 		$1.37M Hold
191,000
– – 0.01% 986
2015
Q1 		$1.64M Sell
191,000
-60,000
-24% -$537K 0.01% 975
2014
Q4 		$2.5M Buy
+251,000
New +$2.14M 0.01% 935

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royce & Associates's RPRX Position: Q1 2016 in Review

Royce & Associates sold out of Repros Therapeutics Inc. (RPRX) in Q1 2016, closing a stake of 129,000 shares — an estimated $156K sold.

Royce & Associates first reported a position in RPRX in Q4 2014 and held it in 5 quarters. The position peaked at $2.5M in Q4 2014. 53 funds tracked by Wall St. Rank hold RPRX as of Q1 2016.

  • Royce & Associates reported no remaining Repros Therapeutics Inc. position as of Q1 2016 after selling out during the quarter.
  • Royce & Associates sold 129,000 Repros Therapeutics Inc. shares in Q1 2016, an estimated $156K.
  • Royce & Associates first reported a position in Repros Therapeutics Inc. in Q4 2014 and held it in 5 quarters.
  • Royce & Associates's Repros Therapeutics Inc. position peaked at $2.5M in Q4 2014.
  • 53 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2016.

Based on Royce & Associates's 13F filing for Q1 2016, filed 11 May 2016.